A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas

Inclusion Criteria: 1. Males and females ≥ 18 years of age; 2. Life expectancy of at least 3 months; 3. ECOG PS ≤ 1; 4. Acceptable bone marrow and organ function at screening; 5. Ability to swallow and retain oral medications; 6. Negative serum pregnancy test in women of childbearing potential; 7. Measurable disease; 8. Tumor for which standard therapy, including approved anti-PD-1 or anti-PD-L1 therapy, when applicable, does not exist or is no longer effective. For patients enrolling into backfill of dose levels at or below the MTD/RP2D, patients with tumor types known to have a high VISTA expression (such as metastatic malignant pleural mesothelioma of epithelioid histology). Exclusion Criteria: 1. Prior treatment anti-cancer therapy or use of any investigational agent within the past 28 days or 5 half-lives, whichever is shorter; 2. Toxicity from prior chemotherapy that has not resolved to Grade ≤ 1; 3. Radiotherapy within the last 21 days; 4. Primary brain tumors or CNS metastases; 5. Major or minor surgery \< 28 and \<14 days from the start of treatment, respectively; 6. Active autoimmune disease or any medical condition requiring the use of systemic immunosuppressive medications; 7. Endocrinopathies, unless on stable hormone replacement therapy; 8. Active infection requiring systemic therapy; 9. Receipt of live vaccines against infectious diseases within 28 days; 10. HIV positive or an AIDS-related illness; 11. Active/chronic HBV or HCV infection; 12. Uncontrolled CHF (NYHA Class 2-4), angina, MI, CVA, coronary/peripheral artery bypass graft surgery, TIA, or PE in prior 3 months; 13. Cardiac dysrhythmias; 14. Gastrointestinal disease that interferes with receipt of oral drugs; 15. Concomitant malignancy; 16. Pregnant or lactating female;